There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Asensus Surgical (ASXC – Research Report), Cue Health (HLTH – Research Report) and Heron Therapeutics (HRTX – Research Report) with bullish sentiments.
Asensus Surgical (ASXC)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Asensus Surgical, with a price target of $2.00. The company’s shares closed last Tuesday at $0.24, close to its 52-week low of $0.20.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Asensus Surgical with a $2.00 average price target.
See the top stocks recommended by analysts >>
Cue Health (HLTH)
BTIG analyst Mark Massaro reiterated a Buy rating on Cue Health yesterday and set a price target of $2.00. The company’s shares closed last Tuesday at $0.32, close to its 52-week low of $0.28.
According to TipRanks.com, Massaro ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cue Health with a $1.33 average price target, representing a 283.8% upside. In a report issued on November 8, TD Cowen also maintained a Buy rating on the stock with a $1.50 price target.
Heron Therapeutics (HRTX)
In a report released today, Boris Peaker from TD Cowen maintained a Buy rating on Heron Therapeutics, with a price target of $2.50. The company’s shares closed last Tuesday at $0.54, close to its 52-week low of $0.50.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Heron Therapeutics with a $2.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASXC:
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023
- Asensus Surgical Announces Sale of Senhance Robotic System
- Asensus enters agreement with Flex for Luna Surgical System
- Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System
- Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 14, 2023
